$XERS $MRK Merck partnered with Xeris to make a high concentration combination of keytruda with its anti CTLA-4 anti body drug. PD-1/PD-L1 drug category is VERY crowded. The next class of immunotherapy mAb to get crowded is CTLA-4. There is only 2 now, but there are several more in the pipeline. These drug types are used synergistically together. Merck is collaborating with us allows them to make a combination subcutaneous product vs 2 separate infusions. This will help them keep market share in a soon to be crowded field. merck.com/news/merck-presen...